GOVERNMENT SUBMISSIONS
We have been at the forefront of HBOT in Australia since 1996
-
HyperMED (OXYMED) installed the Australian first LOKOMAT (Adult and Pediatric Robotic Gait Assisted Walking) in 2006. The combination effects of HBO and LOKOMAT – a ‘world first’.
-
In Australia, the combination effects of HBO/LOKOMAT are viewed as ‘novel and unique.’
-
Between 2008-2013 HyperMED (Hooper) presented multiple funding submissions under Medicare, TAC/Worksafe and AHPRA (Australian Practitioner Regulatory Authority).
-
Today across the USA, in excess of 1200 medical facilities provide similar HBO applications for chronic neurologic and other complex illness disorders. There are in excess of 500-LOKOMATS worldwide and a growing market for personal exoskeletons assisting patient mobility and functionality.
-
HyperMED pioneering efforts contributed to LOKOMAT funding in South Australia (2013). The Women and Children's Hospital (SA) is fund raising $4M to establish Australia’s leading robotic (LOKOMAT) rehabilitation research clinic. The Royal Melbourne Hospital (2014) is also fund raising for a LOKOMAT.
-
Hyperbaric Oxygenation (HBO @ 1.8-2.0 ATA using 100% O2) is with minimal risk and effective. HBO accelerates immune responses. HBO is non-invasive. HBO increases Oxygen tension into Hypoxic tissue inhibiting opportunistic infections and cellular mutations. HBO Up~Regulates the patients own target specific Stem Cells {an 8-fold (800%) increase in circulating CD34+}; HBO enhances Mitochondrial function, HBO proliferates Vascular Endothelial Growth Factors (VEGF) & Neural Growth Factors (BDNF & GDNF), HBO reduces Telomeres degeneration and more ...
-
HBO Down~Regulates toxic intra and extra cellular inflammatory Cytokines (IL1, 2, 6, 7, 8), Tumour Necrosis Factor Alpha (TNFα), chronic opportunistic Anaerobic (MRSA, VRE) and co-infections (Viral, Bacterial, Parasitic), Cell Sepsis and more ...
-
HBO is the 'integrative bridge' between orthodox medicine and complimentary approaches. Oxygen is essential to quality of life and essential to drug delivery. This multifactor internal healing response is 'unique' to Hyperbaric Oxygenation.
Selected Submissions
* REMOVED IN ACCORDANCE WITH THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION.
-
HyperMED Clinical Research/Hooper Supporting Articles - Summary Master (2012)
-
Hyperbaric Oxygen | Lokomat - TAC Funding Application Evidence Based Support (Hooper 2009)
-
VNI Submission 2009 - Victorian NeuroTrauma 'HyperMED unique & novel approach using Hyperbaric Oxygenation, Lokomat & Cerebrolysin - Spinal Cord Injury, Stroke & Brain Injury' (Hooper 2009)
-
Hyperbaric Oxygen | Lokomat - Tim Holding Minister TAC WorkCover (Hooper 2009)
-
Spinal Cord Injury Submission 2009 - 'HyperMED unique & novel approach using Hyperbaric Oxygenation, Lokomat & Cerebrolysin - Spinal Cord Injury' (Hooper 2009)
-
Cerebral Palsy Functional Outcomes 2009 - 'HyperMED unique & novel approach using Hyperbaric Oxygenation, Lokomat & Cerebrolysin - Cerebral Palsy Adults & Paediatrics' (Hooper 2009)
-
Stroke Foundation Submission 2009 - 'HyperMED unique & novel approach using Hyperbaric Oxygenation, Lokomat & Cerebrolysin - Stroke & Traumatic Brain Injury' (Hooper 2009)
-
HyperMED LOKOMAT Use and Recommendation (Hooper 2009)
-
HyperMED - Australian LOKOMAT Experience (Hooper 2008)
-
Case Studies A5 Booklet - Victorian WorkCover Authority (1997) Hyperbaric Oxygen Funding Application (selected case studies only - this is a large file to down load)
-
HyperMED - Hyperbaric Oxygenation Effects on Blood Flow
HyperMED Newsletters & Patient Experiences (Part Gov Submissions)
* REMOVED IN ACCORDANCE WITH THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION.
-
HyperMED Newsletter Spinal Cord Injury 2009.pdf
-
HyperMED Newsletter Brain Injury - Cerebral Palsy 2008.pdf
-
Lokomat - Cost Effective - Australian Experience HyperMED NeuroRecovery.pdf
-
HyperMED - Cerebral Lupus - Is Recovery Possible - July 2010.2.pdf
-
HyperMED - New Strides In Stroke Recovery and Rehabilitation July 2010.1.pdf
-
HyperMED - Case Study Autism, Attention Deficit, Speech, Global Development Delay, Pervasive Development Disorder.pdf
-
HyperMED Media NEWS July 09.pdf
-
HyperMED Media NEWS March 092.pdf
-
HyperMED Newsletter Spinal Cord Injury 2009.pdf
-
HyperMED Newsletter Brain Injury - Cerebral Palsy 2008.pdf
-
HyperMED June July 2007.pdf
-
HyperMED NeuroRecovery May 2007.pdf
-
HyperMED Lokomat NeuroRecovery Newsletter March 2007.pdf
-
HyperMED Newsletter March 2007.pdf
-
HyperMED Newsletter Feb 2007.pdf
-
HyperMED Lokomat Use and Recommendation Dec 2006.pdf
-
HyperMED NeuroRecovery Foundation Dec 2006.pdf
-
HyperMED LOKOMAT Dec 2006.pdf
-
HyperMED Newsletter September 2006.pdf
-
HyperMED Newsletter August 2006.pdf
-
HyperMED SUPPORT - Brain Injured Children.pdf
-
HYPOXIC INDUCED APOPTOSIS - HyperMED.pdf
-
Veterans - HBOT TBI, PTSD, Depression.pdf
-
Hyperbaric Oxygenation Safety Requirements.pdf
-
HyperMED HBOT effects on Blood Flow - graphic.pdf
-
Hyper%20med%20Herald%20Sun%20Article.pdf
Hyperbaric Oxygenation Promotes - NEURORECOVERY & NEUROGENESIS
-
Hyperbaric Oxygenation UP REGULATES ('Good Guys') Cerebral & Spinal Cord Oxygenation; Neural Protective; Stem Cell (CD34+) Mobilization via NOS; Neural Stem Cell Proliferation in Subventricular Zone (SVZ) and Hippocampal Dentate Gyrus (DG); Beta-Catenin & Wnt-3; Nrf2 Antioxidant; IL-10 and TGF-Beta; Glial Cell Derived Neurotrophic Nerve Growth Factors (GDNF); Brain Derived Growth Factors (BDNF); Vascular Endothelial Growth Factors (VEGF); Fibroblast Growth Factors (FGF); Human Microvascular Endothelial Cells (HMEC-1) and Coronary Artery Endothelial cells (CAECs) promoting Angiogenesis; improves Blood Brain Barrier function; Mitochondrial Function; Nitrous Oxide Synthase; Reverse Steal (diversion blood from non-injured tissues into injured tissue); activates (switches-on) dormant inactive neurons within Penumbra Zone; Glucose Uptake into ischemic core; Fosters Plasticity by reducing Nogo-A; induces Neuroplasticity in Chronic Neurologic Conditions
-
Hyperbaric Oxygenation DOWN REGULATES ('Bad Guys') Infarction Size and injury reoccurrence; Hypoxic Induced Cascade (Hypoxic-Inducible Factor Alpha); local and systemic Inflammatory Cytokines - IL-1, IL2, IL-6, and Tumor Necrosis Factor -alpha (TNF-a); Macrophage Inflammatory Protein-1α (MCP-1), c-Jun N-Terminal Kinases (JNKs), and Matrix Metalloproteinase-9 (MMP-9) causing Blood Brain Barrier inflammation, Hemorrhage and Extracellular Vascular Matrix degeneration; Prostaglandin E2 and Cyclo-oxygenase-2 mRNA; Polymorphonuclear leukocytes (PMNL), Endothelial Adhesion Molecule, E-selectin and Intracellular Adhesion Molecule-1 (ICAM-1) via Nitrous Oxide Synthase; Lactate and Pyruvate in the cerebrospinal fluid.